



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 09/22/2023 12:14 Received: 09/22/2023 12:14

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Leflunomide as Metab (Teriflunomide), S/P, 30000, ng/mL, NMRL

Reporting Limit: 500 ng/mL
Synonym(s): Leflunomide Metabolite
Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL.
Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL.
THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE LEFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and pregnancy.
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

Testing performed at NMS Labs, Inc.
200 Welsh Road
Horsham, PA 19044-2208
CLIA 39D0197898

Reported Date: 2023.09.22 12:15

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F322000014
WX0000003826
Printed D&T: 09/22/23 12:15

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002353

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1